Geron to Discuss Top-Line Results from IMerge Phase 3 Call Transcript
Good morning, everyone. Welcome to the Geron Corporation call for Top Line Results from IMerge Phase III. I'm Olivia Bloom, Geron's Executive Vice President of Finance and Chief Financial Officer. I'm joined today by the following members of Geron's management team: Dr. John Scarlett, Chairman and Chief Executive Officer; Dr. Faye Feller, Executive Vice President and Chief Medical Officer; and Anil Kapur, Executive Vice President of Corporate Strategy and Chief Commercial Officer.
Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, timelines, expectations and other projections, including those relating to imetelstat's therapeutic potential and potential regulatory approval of imetelstat, our plans to submit regulatory applications for marketing approval in the United States and EU, potential market opportunities, anticipated clinical plans and commercial events, the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |